American Regent, Inc., a Daiichi Sankyo Group company, today announced results from the phase 3 HEART-FID trial of INJECTAFER® (ferric carboxymaltose injection) for the treatment of iron deficiency in adult heart
Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, have announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III to improve exercise capacity. The company reported that with this approval, INJECTAFER is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency.
INJECTAFER is now the first and only intravenous iron replacement therapy indicated for adult patients with heart failure who have iron deficiency
. | June 5, 2023
Treatment with Injectafer significantly improved exercise capacity compared to placebo in a randomized clinical trial in adult patients with heart failure.